This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pitt, B. Search for Related Content PubMed PubMed Citation Articles by Pitt, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Other heart failure Related Article

(Circulation. 2004;110:1714-1716.)
© 2004 American Heart Association, Inc.

Editorial

A New HOPE for Aldosterone Blockade?

Bertram Pitt, MD

From the University of Michigan School of Medicine, Ann Arbor.

Correspondence to Bertram Pitt, MD, Department of Internal Medicine, University of Michigan Medical School, 1500 E Medical Center Dr, 3910 Taubman Center, Ann Arbor, MI 48109-0366. E-mail bpitt@umich.edu

Key Words: Editorials • aldosterone • coronary disease • angiotensin

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Aldosterone is increasingly recognized to play an important role in the pathophysiology of heart failure due to systolic left ventricular dysfunction (SLVD) and aldosterone blockade (AB) to be effective in reducing mortality and morbidity in patients with severe chronic heart failure and heart failure due to SLVD after myocardial infarction.^1,2 AB has also been shown to reduce blood pressure and target-organ damage in patients with essential hypertension.³ The effect of AB on mortality and morbidity will soon be investigated in patients with mild to moderate heart failure due to SLVD and in patients with heart failure with preserved left ventricular systolic function. Although AB has been shown to be effective in patients with SLVD and in those with essential hypertension without SLVD, increasing evidence suggests that it may have an even greater role in patients with atherosclerosis of the coronary and other vascular beds.

See p 1819

Role of Aldosterone in Vascular Damage and Its Consequences

It is reasonable to assume that aldosterone influences vascular function because mineralocorticoid receptors are expressed in vascular endothelial and smooth muscle cells as well as in cardiac fibroblasts and cardiomyocytes.⁴ Many of the pathophysiological effects of angiotensin II on the myocardium and vascular wall may, in a large part, be due to aldosterone and can be blocked by AB as well as by an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB); however, it appears that the combination of an AB with an ACE-I or ARB may be more effective than either alone in preventing myocardial and vascular inflammation and remodeling. Although . . . [Full Text of this Article]

Related Article:

Cardiac Specific Increase in Aldosterone Production Induces Coronary Dysfunction in Aldosterone Synthase–Transgenic Mice

Anne Garnier, Jennifer K. Bendall, Sebastien Fuchs, Brigitte Escoubet, Francesca Rochais, Jacqueline Hoerter, Johnny Nehme, Marie-Lory Ambroisine, Noeleen De Angelis, Gilles Morineau, Pauline d’Estienne, Rodolphe Fischmeister, Christophe Heymes, Florence Pinet, and Claude Delcayre
Circulation 2004 110: 1819-1825. [Abstract] [Full Text]